Pharma majors Ranbaxy and Aurobindo Pharma today said that they have received final approval from the US Food and Drug Administration(USFDA) to manufacture and market Sumatripan Succinate.
While Ranbaxy got approval for 25 and 50 mg varients of the drug, Aurobindo got the approval for 100 mg tablets apart from 25 and 50 mg tablets.
The Office of Generic Drugs, USFDA, has determined the Ranbaxy formulations to be bio-equivalent and have the same therapeutic effect that of the reference listed drug Imitrex manufactured by GlaxoSmithkilne.
The drug is used in the treatment of migraine in adults. Ranbaxy shares were trading at Rs 275.25, nearly 14.25 per cent higher than Monday's close. Aurobindo stock was trading at Rs 615.05, nearly 3.35 per cent down from Monday's close.
